Sustainability & Climate

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

Echo Water's new Echo One promises ultra-pure, hydrogen-rich water on demand. But is the cutting-edge science and technology worth the premium price tag?

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

With an expanded Boehringer Ingelheim deal and a new CMO, Enara Bio is set to take its novel 'Dark Antigen' therapy into human trials in 2026.

The special mission aviation provider completes a buyout of Bain Capital, consolidating NTC Group's ownership and securing new capital to expand its services.

EF Adventures' new Tour de France tours let fans ride race routes and party with pros, setting a new standard for immersive sports tourism.

Rani Therapeutics starts Phase 1 trials for an oral obesity drug, challenging the injectable market with a novel delivery system and a dual-action compound.

With major backing from Goldman Sachs, a biotech firm is advancing a potentially life-changing gene therapy for a rare, progressive form of blindness.

With over 30 years of experience, Leonard Carder takes the helm at 4M Building Solutions, signaling a new chapter of aggressive acquisition and innovation.

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Renowned scientist Eric Hoek becomes Executive Chairman at Active Membranes, aiming to commercialize a technology that could cut water treatment costs by 50%.

After success in Europe, Allotex gets FDA nod to begin U.S. trials for its tissue-based presbyopia treatment, offering new hope for millions.

At CES 2026, LumiMind's BCI tech promises to guide you to sleep and power thought-controlled games, raising major scientific and ethical questions.

The acquisition, advised by Westcove Partners, highlights the trend of private equity-fueled consolidation aimed at enhancing clinical trial access.

Dexcel Pharma USA acquires Zubsolv®, a key opioid addiction therapy, signaling a major strategic shift into the branded drug market in the U.S.

With a C$20M financing deal, Generation Mining is pushing its 'shovel-ready' Marathon copper-palladium project closer to construction.

An updated study confirms a 70-year mine life and $2B value for Karnalyte's Wynyard potash project, but the multi-billion dollar financing remains key.

After its successful 2025 IPO, CoastalSouth Bancshares celebrates its NYSE listing. Can the regional bank leverage Wall Street capital without losing its local focus?

As legacy brand Hamilton Beach heads to a major conference, its high-stakes pivot from kitchen gadgets to health tech will be under the microscope.